A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases

Roshanravan N., Tutunchi H., Najafipour F., DASTOURİ M., Ghaffari S., Jebeli A.

JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH, cilt.14, sa.2, ss.77-83, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 14 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.34172/jcvtr.2022.14
  • Dergi Adı: JOURNAL OF CARDIOVASCULAR AND THORACIC RESEARCH
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.77-83
  • Anahtar Kelimeler: Cardiovascular Diseases, CRISPR/Cas9, Genome Editing Strategy, GENOME, ABLATION, MODEL
  • Ankara Üniversitesi Adresli: Evet

Özet

Cardiovascular diseases (CVDs) remain major causes of global mortality in the world. Genetic approaches have succeeded in discovery of the molecular basis of an increasing number of cardiac diseases. Genome editing strategies are one of the most effective methods for assisting therapeutic approaches. Potential therapeutic methods of correcting disease-causing mutations or of knocking out specific genes as approaches for the prevention of CVDs have gained substantial attention using genome editing techniques. Recently, the clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9 (CRISPR/Cas9) system has become the most widely used genome-editing technology in molecular biology due to its benefits such as simple design, high efficiency, good repeatability, short-cycle, and cost-effectiveness. In the present review, we discuss on the possibilities of applying the CRISPR/Cas9 genome editing tool in the CVDs.